Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC1 | P33527 | 3/20 | 0.50 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.48 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.48 |
| ▸ | MASP2 | O00187 | 1/20 | 0.48 |
| ▸ | RBP4 | P02753 | 2/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | CFD | P00746 | 1/20 | 0.43 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9505610 | 0.77 | NPSR1 (0.40) | KMT2AMEN1 | |
| SCHEMBL8359274 | 0.76 | ABCC1 (0.54) | ABCC1MASP2KMT2AMEN1PKM | |
| SCHEMBL11107904 | 0.76 | ALDH1A1 (0.50) | KMT2AMEN1 | |
| SCHEMBL5476751 | 0.74 | LMNA (0.39) | KMT2AMEN1PKMLMNA | |
| SCHEMBL432229 | 0.74 | KCNK2 (0.55) | KCNK2KCNK10MASP2GRIK1KMT2A | |
| SCHEMBL6434411 | 0.73 | GRIK1 (0.59) | ABCC1RBP4GRIK1KMT2AMEN1 | |
| SCHEMBL6250057 | 0.73 | HSD17B10 (0.43) | KMT2AMEN1 | |
| SCHEMBL6250051 | 0.72 | PDK1 (0.33) | KMT2AMEN1 | |
| SCHEMBL4749159 | 0.70 | DHODH (0.69) | MASP2GRIK1KMT2AMEN1PKM | |
| SCHEMBL13936398 | 0.70 | DHODH (0.64) | ABCC1MASP2KMT2AMEN1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | CPA3, HNMT, CMA1 | ABCC1 2075/4885KCNK2 3002/4885KCNK10 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.